Cormedix inc. (CRMD)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenue
Net sales

283

429

329

224

210

189

2

0

-

-

Cost of sales

373

396

114

366

-318

-445

-201

0

-

-

Gross profit (loss)

-89

33

214

-142

-108

-256

-199

0

-

-

Operating Expenses
Research and development

11,052

18,822

24,486

15,735

6,281

1,318

1,226

1,142

4,058

5,494

Selling, general and administrative

-

-

8,652

8,883

10,263

7,326

3,488

1,857

3,148

3,012

Selling, general and administrative

9,865

8,074

-

-

-

-

-

-

-

-

Total operating expenses

20,917

26,897

33,138

24,618

16,545

8,645

4,715

2,999

7,206

8,507

Loss From Operations

-21,007

-26,864

-32,924

-24,760

-16,653

-8,902

-4,915

-2,999

-7,206

-8,507

Other Income (Expense)
Interest income

322

36

110

126

60

2

0

1

12

23

Foreign exchange transaction loss

-21

-0

-13

-8

-6

-150

0

-

-

-

Loss on issuance of preferred stock, convertible notes and warrants

-

-

-

-

0

89

945

0

-

-

Value of warrants issued in connection with backstop financing

-

-

-

-

-1,583

0

-

-

-

-

Foreign exchange transaction gain (loss)

-

-

-

-

-

-

-4

0

29

391

Change in fair value of derivative liabilities

-

-

-177

0

0

-8,848

-363

0

-

-

Loss on modification of equity instruments and extinguishment of derivative liabilities

-

-

-

-

0

2,462

0

-

-

-

Loss on modification of equity instruments and extinguishment of derivative liabilities

-

-

-

-

-

-

-1,459

0

-

-

Interest expense

787

1

5

1

3

2

1,444

382

0

3,093

Total other income (expense)

-485

34

-

-

-

-

-

-

-

-

Net Loss Before Income Taxes

-21,493

-26,829

-

-

-

-

-

-

-

-

Total income (expense)

-

-

-

-117

1,533

11,551

-

-

-

-

Total other income (expense)

-

-

-85

-

-

-

-

-

-

-

LOSS BEFORE INCOME TAXES

-

-

-

-

-

-

-

-3,380

-7,165

-11,186

Tax benefit

-5,060

-

-

-

-

-

-

0

-493

-280

Net Loss

-16,433

-26,829

-33,009

-24,643

-18,187

-20,453

-9,133

-3,380

-6,671

-10,905

Other Comprehensive Loss
Unrealized loss from investment

0

-

13

11

-24

0

-

-

-

-

Foreign currency translation (loss) gain

-

-

4

8

-12

108

-9

-

-

-

Total other comprehensive (loss) income

-

-

-17

-19

36

-108

-

-

-

-

Foreign currency translation loss

0

-1

-

-

-

-

-

-

-

-

Total other comprehensive loss

0

-1

-

-

-

-

-

-

-

-

Comprehensive Loss

-16,432

-26,831

-32,992

-24,624

-18,224

-20,345

-9,142

-

-

-

Net Loss

-16,433

-26,829

-33,009

-24,643

-18,187

-20,453

-9,133

-3,380

-6,671

-10,905

Deemed dividend as a result of warrant modification

-369

-

-

-

-

-

-

-

-

-

Deemed dividend as a result of exchange of convertible note and Series C-2, Series D and Series F preferred stock, related party

-26,733

-

-

-

-

-

-

-

-

-

Dividends, including deemed dividends

-

-

-

-

-33

-82

-384

0

-

-

Net Loss Attributable to Common Shareholders

-43,535

-26,829

-

-

-18,220

-20,536

-9,517

-3,380

-

-

Net Loss Per Common Share – Basic and Diluted (in Dollars per share)

-1.80

-1.51

-0.60

-0.65

-0.58

-0.96

-0.69

-0.30

-0.58

-1.15

Weighted Average Common Shares Outstanding – Basic and Diluted (in Shares)

24,152

17,816

55,141

37,967

31,343

21,441

13,823

11,408

11,408

-

WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC AND DILUTED

-

-

-

-

-

-

-

-

-

9,473